Overview

Pulmonary sarcomatoid_MEDI4736+Treme

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Antibodies, Monoclonal
Durvalumab
Tremelimumab